S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in
NASDAQ:GNMX

Aevi Genomic Medicine Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.17
0.00 (0.00 %)
(As of 02/3/2020)
Add
Compare
Today's Range
$0.15
Now: $0.17
$0.18
50-Day Range
$0.17
MA: $0.17
$0.19
52-Week Range
$0.11
Now: $0.17
$0.35
Volume2.95 million shs
Average Volume3.16 million shs
Market Capitalization$12.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Aevi Genomic Medicine logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNMX
Previous SymbolNASDAQ:MDGN
CUSIPN/A
Phone610-254-4201
Employees14
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.12 per share

Profitability

Net Income$-30,770,000.00

Miscellaneous

Market Cap$12.89 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

0.63 out of 5 stars

Medical Sector

1293rd out of 1,958 stocks

Biological Products, Except Diagnostic Industry

151st out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Receive GNMX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions

What stocks does MarketBeat like better than Aevi Genomic Medicine?

Wall Street analysts have given Aevi Genomic Medicine a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aevi Genomic Medicine wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Aevi Genomic Medicine's earnings last quarter?

Aevi Genomic Medicine, LLC (NASDAQ:GNMX) issued its earnings results on Thursday, November, 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.03.
View Aevi Genomic Medicine's earnings history
.

Who are Aevi Genomic Medicine's key executives?

Aevi Genomic Medicine's management team includes the following people:
  • Mr. Michael F. Cola, CEO, Pres & Director (Age 59)
  • Mr. Brian D. Piper, CFO & Corp. Sec. (Age 47)
  • Dr. Garry A. Neil, Chief Scientific Officer (Age 65)

Who are some of Aevi Genomic Medicine's key competitors?

What other stocks do shareholders of Aevi Genomic Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aevi Genomic Medicine investors own include Novavax (NVAX), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Protalix BioTherapeutics (PLX), iBio (IBIO), Immunomedics (IMMU), Actinium Pharmaceuticals (ATNM), Biocept (BIOC) and MEI Pharma (MEIP).

What is Aevi Genomic Medicine's stock symbol?

Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."

What is Aevi Genomic Medicine's stock price today?

One share of GNMX stock can currently be purchased for approximately $0.17.

How much money does Aevi Genomic Medicine make?

Aevi Genomic Medicine has a market capitalization of $12.89 million. The biotechnology company earns $-30,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does Aevi Genomic Medicine have?

Aevi Genomic Medicine employs 14 workers across the globe.

What is Aevi Genomic Medicine's official website?

The official website for Aevi Genomic Medicine is www.aevigenomics.com.

Where are Aevi Genomic Medicine's headquarters?

Aevi Genomic Medicine is headquartered at 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087.

How can I contact Aevi Genomic Medicine?

Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.